Lisata Therapeutics, Inc.
LSTA
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trialā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.06
Price-12.34%
-$0.29
1Y
Price
Market Cap
$18.037m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-6592.9%
EBITDA Margin-6655.7%
Net Profit Margin-5651.4%
Free Cash Flow MarginRevenue
$1.070m
+7.0%
1y CAGR-31.0%
3y CAGR-23.2%
5y CAGREarnings
-$18.923m
+5.3%
1y CAGR+23.7%
3y CAGR-6.6%
5y CAGREPS
-$2.23
+7.1%
1y CAGR+29.8%
3y CAGR+12.2%
5y CAGRBook Value
$20.775m
$25.160m
Assets$4.385m
Liabilities$47k
DebtDebt to Assets
0.2%
-
Debt to EBITDAFree Cash Flow
-$16.404m
+15.3%
1y CAGR+8.4%
3y CAGR+7.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company